Purdue-funded textbook scrapped at Toronto college; Lupin, Sunovion settle Lunesta patent fight;

@FiercePharma: GSK's Witty speaks small to think big. Report |  Follow @FiercePharma

> A complaint about perceived drug industry involvement in a pain management course for medical students has prompted the University of Toronto to revamp its curriculum. Story

> Lupin Pharmaceuticals settled its ongoing patent fight with Sunovion Pharmaceuticals over the sleep drug Lunesta with a deal that allows the generics maker to sell its version by November 2013. News

> Cephalon has tapped J. Kevin Buchi as CEO--a job he has been doing on an interim basis since August--after the recent death of company founder Frank Baldino. Report

> Mylan agreed to pay $65 million to settle a lawsuit by the U.S. and Texas alleging it inflated prescription drug prices, increasing the cost of reimbursing pharmacies and other providers. Item

> At least five workers were killed and eight others injured in an explosion at a Quanxin Pharmaceutical plant in southwest China's Yunnan province. Story

> Indian pharmaceutical companies led by Glenmark, Aurobindo and Sun Pharma maintained their No. 1 position in the U.S. generics market, by bagging 33 percent of 2010's generics approvals. Article

> India has rejected Abbott Laboratories' drug patent application for its combination HIV drug Kaletra. Report

> Sun Pharmaceutical Industries stock rose 1.36 percent after the company won tentative FDA approval for a generic version of Roche's Boniva. News

Biotech News

@FierceBiotech:  Burrill predicts big surge in biotech buyouts for 2011. News | Follow @FierceBiotech

> Genocea taps $35M venture round as it seeks new CEO. Item 

> Inspire shares tank after lead CF drug fails Phase III. Report

> Roche snaps up Marcadia Biotech. Story 

> 2010: Another blah year at FDA as new drug approvals slip. News 

> GSK's Witty looks to new blockbusters to reverse a bleak trend. Article

Biotech IT News

> RedOak readies natural-intelligence software for drug development. News 

> Jupiter trial results face calcium/cholesterol conundrum. Report 

> NCI trial-revamp plans call for IT overhaul. Story 

> EDC can aid in adverse event reporting. News 

> Poll: Pharma among industries needing more regulation. Article 

> FDA too rigid in review of drugs for critically ill. Item

And Finally... The Australian government is under fire for failing to maintain a register of gifts and benefits given to its Health Department officials by multibillion-dollar pharmaceutical companies. Report

Suggested Articles

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.